Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 156 Jul 27 – Oct 24, 2026
- Disclosed funding
- $5.9B 121 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| BB BrainChild BioCompany profile BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma. BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma. | $116M | Series A | Biotech | United States | Investors Undisclosed | |
| CB Cloverleaf BioCompany profile Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical. Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical. | $33M | Seed | Biotech | United States | Investors | |
| YB Yngvi BioCompany profile A Copenhagen crop-protection biotech developing protein-based pest-control products designed to target specific agricultural pests while reducing harm to beneficial insects and reliance on conventional pesticides. A Copenhagen crop-protection biotech developing protein-based pest-control products designed to target specific agricultural pests while reducing harm to beneficial insects and reliance on conventional pesticides. | €1.3M | BII Venture House convertible loanUndisclosed | Biotech, Agritech | Denmark | Investors | |
| PI PorMedTec, Inc.Company profile A biotechnology company producing gene-edited donor pigs for research and planned clinical trials in organ transplantation. A biotechnology company producing gene-edited donor pigs for research and planned clinical trials in organ transplantation. | ¥1B | FundingUndisclosed | Biotech | Japan | Investors | |
| V VaxdynCompany profile Vaxdyn develops vaccines against antimicrobial-resistant bacteria, including its lead candidate K-VAX for Klebsiella pneumoniae and Acinetobacter baumannii. Vaxdyn develops vaccines against antimicrobial-resistant bacteria, including its lead candidate K-VAX for Klebsiella pneumoniae and Acinetobacter baumannii. | €11M | Series A | Biotech | Spain | Investors | |
| AI ANRis, Inc.Company profile A biotechnology company developing siRNA medicines designed to suppress disease-causing mutations while preserving normal gene function. A biotechnology company developing siRNA medicines designed to suppress disease-causing mutations while preserving normal gene function. | ~¥220M | FundingUndisclosed | Biotech | Japan | Investors | |
| H HelogenCompany profile Helogen builds autonomous in-orbit manufacturing systems for biomaterials and biologics. Helogen builds autonomous in-orbit manufacturing systems for biomaterials and biologics. | $7.1M | Seed | Biotech, Space tech | United States | Investors | |
| MF MOA FoodtechCompany profile MOA Foodtech uses AI-guided fermentation to turn agricultural and food-processing byproducts into functional protein and ingredient products for food and pet-food manufacturers. Its models help select suitable microorganisms and process conditions for each feedstock; the company also offers custom development and modular systems for valorising starch-rich side streams. MOA Foodtech uses AI-guided fermentation to turn agricultural and food-processing byproducts into functional protein and ingredient products for food and pet-food manufacturers. Its models help select suitable microorganisms and process conditions for each feedstock; the company also offers custom development and modular systems for valorising starch-rich side streams. | €3.3M | €3.3 million financing roundUndisclosed | Biotech, Foodtech | Spain | Investors | |
| MT Metagen TherapeuticsCompany profile A clinical-stage biotechnology company developing microbiome-based therapies using fecal microbiota transplantation. A clinical-stage biotechnology company developing microbiome-based therapies using fecal microbiota transplantation. | ¥190M | Series B extension (first close)Series B | Biotech | Japan | Investors | |
| S Science4BeautyCompany profile A Polish skincare company using a recombinant conotoxin active ingredient in anti-wrinkle creams and other products sold directly to consumers and through aesthetic-medicine channels. A Polish skincare company using a recombinant conotoxin active ingredient in anti-wrinkle creams and other products sold directly to consumers and through aesthetic-medicine channels. | PLN 7M | Series A | Biotech | Poland | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 27, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
9rounds3led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
5rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.